Sian Harding is Professor of Cardiac Pharmacology at the National Heart and Lung Institute, Imperial College, as well as Institute Lead for Women for Athena Swan, and a co-investigator within the UKRMP Immunomodulation Hub.
She obtained her Ph.D. in Pharmacology from King's College, London in 1981, and since then the primary focus of her work has been cardiomyocyte function in the failing heart. This has extended to gene therapy to modulate cardiomyocyte function, and she is Scientific PI for the UK's first clinical trial on myocardial gene therapy. More recently the scope has extended to the characterisation of cardiomyocytes derived from embryonic stem cells, and their use in cardiac repair, tissue engineering and drug discovery.
Professor Harding is Past-President of the European Section of the International Society for Heart Research and Fellow of the AHA, ESC and ISHR. She sits on the Nuffield Council on Bioethics and the Scientific Advisory Board of the PPP "Stem Cells for Safer Medicines".
Professor Harding delivered her Inaugural Lecture, entitled 'Reviving the Failing Heart: one cell at a time', on 3 April 2007. The abstract and other details of the lecture can be found here.
et al., 2018, Estrogen deficiency compromised the β2AR-Gs/Gi coupling: implications for arrhythmia and cardiac injury., Pflugers Arch
et al., 2018, Investigation of cardiac fibroblasts using myocardial slices., Cardiovasc Res, Vol:114, Pages:77-89
et al., 2017, Overexpression of hypoxia-inducible factor 1 alpha improves immunomodulation by dental mesenchymal stem cells, Stem Cell Research & Therapy, Vol:8, ISSN:1757-6512
et al., 2017, Electrospun aniline-tetramer-co-polycaprolactone fibers for conductive, biodegradable scaffolds, Mrs Communications, Vol:7, ISSN:2159-6859, Pages:375-382
et al., Structural and functional plasticity of myocardial slices in response to prolonged mechanical loading and unloading in vitro, European Society of Cardiology Congress 2017